Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Approval

Clinical Trials

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

The decision underscores the FDA’s insistence on well‑controlled efficacy data over single‑arm results.

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy